We report the findings from a randomized, parallel study designed to evaluate nicotine pharmacokinetics (PK) following 10 min of ad libitum use of electronic nicotine delivery system (ENDS) in four flavor variants. Subjects were randomized an investigational product (IP) and blood samples were collected for PK assessments during a test session. Primary endpoints were baseline-adjusted values of maximum plasma nicotine concentration (Cmax) and area under the nicotine concentration-vs-time curve up to 60 min (AUCnic0–60). Baseline-adjusted mean Cmaxranged from 6.53 to 8.21 ng/mL, and mean AUCnic0–60ranged from 206.87 to 263.52 ng min/mL for all ENDS IPs. Results of geometric mean Cmaxand AUCnic0–60values were within 95% confidence intervals (CI) among the ENDS IP flavor variants tested.